|
 Whether or not effective drugs come in time to turn around the
world's worst epidemic of the virus ravaging three West African
countries, the world will want stockpiles to protect against
inevitable future outbreaks, experts say.
So a new structure, which some call "Ebolanomics", is needed to
revise the business model for a previously neglected disease.
GAVI, the global vaccines alliance, is already working to figure out
how to procure a future Ebola vaccine at an affordable price, and
drugmakers are considering how much to invest in a disease that,
until this outbreak, had infected barely 2,400 people in total in
four decades.
Even now Ebola is unlikely to become a big money-spinner for Western
pharmaceutical companies, since it afflicts the poor in Africa and
the need for medical stockpiles in developed countries will be
modest.
Vaccine makers, governments, experts and health agencies are meeting
at the World Health Organization's (WHO) headquarters in Geneva on
Thursday to come up with some answers.
"What GAVI is going to do is look at all the potential options and
ask whether we should create an artificial market," GAVI's chief
executive Seth Berkley told Reuters.
That could include making advance commitments to buy so many million
doses of a vaccine, with an added incentive of offering a much
higher price for the first tranche of any purchase.
“There are no economics now because we do not need a vaccine in the
United States or Spain or the UK, though that's not to say people
wouldn't buy it right now because people are panicking. The problem
is the countries that need it are very, very poor,” Berkley said.
Past Ebola outbreaks have killed few people and there have been no
recorded Ebola deaths in 22 out of the 38 years since the virus was
first identified, helping to explain the limited vaccine effort to
date, even though Ebola is a simpler target than notoriously tricky
ones like HIV and malaria.
This time, however, according to an analysis by the catastrophe risk
management firm RMS, the Ebola epidemic in West Africa has the
potential to be the most deadly infectious disease event since the
1918 flu pandemic.
It has already killed nearly 5,000 people, nearly all of them in
Liberia, Sierra Leone and Guinea. The WHO believes it can turn the
tide if 70 percent of Ebola patients get treatment or a safe burial,
but hitting that tipping point is a challenge.
BETTER PREPARED
Brian Greenwood, a professor of clinical tropical medicine at the
London School of Hygiene and Tropical Medicine, said the only
sensible response to the worldwide alarm caused by such an epidemic
is to be far more ready for the next one.
"We have to be better prepared, the way we are for big flu epidemics
or big meningitis outbreaks," he said. "We have to have a stockpile.
That's what we do with yellow fever and that's what happens with
meningitis, so there is a precedent there."
If they are ready in time and in sufficient doses, there's little
doubt effective Ebola vaccines and medicines could make a
significant dent in the current deadly epidemic.
Researchers are already testing two candidate vaccines from
GlaxoSmithKline and NewLink Genetics, with a third from Johnson &
Johnson set to enter human trials in January. Thousands of frontline
healthcare workers should start receiving them from the start of
next year.
[to top of second column] |
Scaling up to the millions needed for mass immunization is a project
for later in 2015 and will require financial backing from
governments and donor organizations, as well as likely indemnity for
firms against losses or claims.
Drugmakers and health experts alike never imagined they'd be in this
position, so the prospect of an epidemic lasting into 2016 and of
demand for drugs for future stockpiles is forcing a major
realignment.
"This situation requires new ways of working and thinking,"
GlaxoSmithKline's chief executive Andrew Witty said this week as he
declared his firm will happily work with rivals in what he described
as "phenomenal collaboration" in the Ebola fight.
INVESTOR ATTENTION
Investors are taking note, with the shares of small biotech
companies most exposed the success or failure of a single product
liable to jump and dip on scraps of news suggesting either success
or failure.
"In the wake of this catastrophe, there will be drugs, diagnostics
and vaccines that are licensed and available," said Rajeev Venkaya,
now head of vaccines at Takeda Pharmaceutical and formerly with the
Bill & Melinda Gates Foundation.
He expects companies will find a business model that works, helped
by development-stage support from governments and donors.
"You can take those costs out of the future cost of goods of
commercially produced products, which will of course reduce the
price and make it a more sustainable business," he said.
Yet despite fears of greater international spread of the disease,
the basics of Ebolanomics remain uncertain.
Realistically, Ebola is unlikely ever to be a big Western market,
not even for a traveler vaccine, since visitors to West Africa are
even now at very low risk of becoming infected unless they are in
frequent close contact with Ebola cases.
This is not like pandemic flu, which spreads like wildfire,
prompting governments in the West to stockpile large amounts of
vaccines and drugs, leading to windfall profits for drugmakers
during the H1N1 pandemic of 2009 and 2010.
Ebola stockpiles, by contrast, will be small and strategic.
"The only way really for an Ebola vaccine to make money long-term is
likely to be in a scenario where governments stockpile," said Keith
Spencer, a business development analyst at the Wellcome Trust, an
international health charity.
"But we don't have a vaccine yet that we know works, and until
you've got a product, it's hard to know whether or not anyone is
gong to want to buy it."
(Editing by Giles Elgood)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
